$FDMT News

4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapy

HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

4DMT Announces New Employment Inducement Grants

Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25

4DMT to Host Investor Day on October 21, 2026

4D Molecular: Reiterate 'Buy' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial Underway

B of A Securities Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $33

OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs

4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME

4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight, Announces $20 Price Target

4DMT Announces New Employment Inducement Grants

4DMT to Participate in Upcoming Investor Conferences

OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates

4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

B. Riley Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $37

4D Molecular's One-Shot Eye Therapy Delivers Two-Year Win